Longwood Fund
Newleos Therapeutics Launches with $93.5M to Develop Novel Neuropsychiatric Treatments
Newleos Therapeutics, Longwood Fund, neuropsychiatry, anxiety disorders, substance use disorders, Roche, GABA A -γ1, clinical trials
Actionable Insights Powered by AI
Newleos Therapeutics, Longwood Fund, neuropsychiatry, anxiety disorders, substance use disorders, Roche, GABA A -γ1, clinical trials